

Marianna Cavazza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/291628/publications.pdf>

Version: 2024-02-01

12
papers

273
citations

1307594

7
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

477
citing authors

#	ARTICLE	IF	CITATIONS
1	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 19-29.	2.8	59
2	Social/economic costs and quality of life in patients with haemophilia in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 53-65.	2.8	53
3	Health care costs of influenza-related episodes in high income countries: A systematic review. <i>PLoS ONE</i> , 2018, 13, e0202787.	2.5	42
4	De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making. <i>Health Policy and Technology</i> , 2016, 5, 47-64.	2.5	38
5	Stakeholders involvement by HTA Organisations: Why is so different?. <i>Health Policy</i> , 2012, 105, 236-245.	3.0	26
6	Governing through Evidence: A Study of Technological Innovation in Health Care. <i>Journal of Public Administration Research and Theory</i> , 2014, 24, 843-877.	3.3	16
7	Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 189-199.	2.5	16
8	Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1101.	2.6	8
9	Social Economic Costs, Health-Related Quality of Life and Disability in Patients with Cri Du Chat Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5951.	2.6	6
10	The economic impact of compassionate use of medicines. <i>BMC Health Services Research</i> , 2021, 21, 1303.	2.2	5
11	Patient access to oral nutritional supplements: Which policies count?. <i>Nutrition</i> , 2020, 69, 110560.	2.4	3
12	Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals. <i>Global & Regional Health Technology Assessment</i> , 2019, 2019, 228424031986137.	0.1	1